Product News

Share this article:
The FDA has granted Caraco Pharmaceutical Laboratories approval for its Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Tablets indicated as short-term monotherapy for the management of exogenous obesity. According to IMS data, for the 12 months ended June 2007, Phentermine HCl generic and brand products (Adipex-P) combined had annual sales of approximately $34 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.